Efficacy and Safety of Omalizumab in Children (6 - <12 Years) With Moderate-Severe, Inadequately Controlled Allergic Asthma - Related Studies

Efficacy and Safety of Omalizumab in Children (6 - <12 Years) With Moderate-Severe, Inadequately Controlled Allergic Asthma

This study is ongoing, but not recruiting participants.

Study NCT00079937. Last updated on December 20, 2007. Information provided by Novartis

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Asthma

2	More general conditions related to this trial
		Bronchial Diseases
		Hypersensitivity
		Hypersensitivity, Immediate
		Immune System Diseases
		Lung Diseases
		Lung Diseases, Obstructive
		Respiratory Hypersensitivity
		Respiratory Tract Diseases

3	Interventions listed in this trial
		Omalizumab
		placebo

4	More general drug interventions related to this trial
		Anti-Allergic Agents
		Anti-Asthmatic Agents
		Pharmacologic Actions
		Respiratory System Agents
		Therapeutic Uses

5	Sponsors listed in this trial
		Novartis